Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
- License Information
-
More Information
Article History
Received: 1 May 2025
Accepted: 17 July 2025
First Online: 1 August 2025
Declarations
:
: A.G. has nothing to disclose. M.R. has received lecture fees or served on advisory boards for AstraZeneca, Boehringer-Ingelheim, Echosens, Eli Lilly, Madrigal, MSD, Novo Nordisk and Target RWE and has performed investigator-initiated research with support from Boehringer-Ingelheim and Novo Nordisk to the German Diabetes Center (DDZ). The research of K.P. is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation): Project number 493659010 in the context of the Clinican Scientist Program (FUTURE-4-CSPMM) and by grants from the German Diabetes Research (DZD) foundation and the Heinrich-Heine-University Düsseldorf.
